Literature DB >> 26060110

Preventing complications in celiac disease: our experience with managing adult celiac disease.

C J Mulder1, N J Wierdsma2, M Berkenpas2, M A J M Jacobs3, G Bouma3.   

Abstract

Celiac disease is, as we know it, rather than being a rare and incurable disease until the 1950's, both quite common in screening studies and readily treatable. Three conditions are triggered by gluten consumption: celiac disease, the skin rash dermatitis herpetiformis and gluten ataxia. We describe our follow up for out clinic management, as evidence based data about such an approach are lacking in current literature. No food, beverages or medications containing any amount of gluten can be taken. Compliance is often difficult especially when patients are asymptomatic. We control a cohort, in daily practice, of over 700 adult patients. The majority of patients manage the diet without any problems. We describe our follow up in general, for serology, laboratory and histology. Forty percent of our newly diagnosed celiac patients do have a BMI over 25 kg/m(2). An appropriate attitude for this problem is lacking. The problem of slowly weaning off Dapsone over 5-10 years in DH is recognized. The bone density is checked in all newly diagnosed celiac patients. We control, if necessary, by telephone and lab controls done in local cities and see our patients only every two years face-to-face for follow up. The main question is if the adherence to a GFD, quality of life and prevention of complications is improved by visiting a dedicated celiac clinic. We hope to standardize this attitude on evidence data in the years to come.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Celiac disease; Follow up; Gluten free diet; Laboratory; Management; Observational studies

Mesh:

Year:  2015        PMID: 26060110     DOI: 10.1016/j.bpg.2015.05.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  9 in total

Review 1.  Pediatric Celiac Disease: Follow-Up in the Spotlight.

Authors:  Francesco Valitutti; Chiara Maria Trovato; Monica Montuori; Salvatore Cucchiara
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

2.  Predictive Factors and Clinical Impact of Deep Remission in Celiac Disease.

Authors:  Marta Silva; Armando Peixoto; Ana Luísa Santos; Pedro Costa-Moreira; Joel Ferreira da Silva; Emanuel Dias; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2020-01-10

Review 3.  Celiac Disease Revisited.

Authors:  João Calado; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2021-03-17

4.  Clinical spectrum of paediatric coeliac disease: a 10-year single-centre experience.

Authors:  Michael W Van Kalleveen; Tim de Meij; Frans B Plötz
Journal:  Eur J Pediatr       Date:  2018-02-01       Impact factor: 3.183

5.  Adult celiac disease with persistent IBS-type symptoms: a pilot study of an adjuvant FODMAP diet.

Authors:  Nick Trott; Anupam Rej; Sarah H Coleman; David S Sanders
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

6.  Diffuse intestinal ulcerations: Diagnostic challenge in a patient with complicated celiac disease.

Authors:  Mirjana Kalauz; Silvija Cukovic Cavka; Viktor Domislovic; Kiarash Pourmodjib; Matija Kalauz; Snjezana Dotlic; Katja Grubelic Ravic; Zeljko Krznaric
Journal:  DEN open       Date:  2022-06-20

Review 7.  Review article: Follow-up of coeliac disease.

Authors:  J A Tye-Din
Journal:  Aliment Pharmacol Ther       Date:  2022-07       Impact factor: 9.524

Review 8.  The Spectrum of Differences between Childhood and Adulthood Celiac Disease.

Authors:  Rachele Ciccocioppo; Peter Kruzliak; Giuseppina C Cangemi; Miroslav Pohanka; Elena Betti; Eugenia Lauret; Luis Rodrigo
Journal:  Nutrients       Date:  2015-10-22       Impact factor: 5.717

9.  Gluten-free food database: the nutritional quality and cost of packaged gluten-free foods.

Authors:  Benjamin Missbach; Lukas Schwingshackl; Alina Billmann; Aleksandra Mystek; Melanie Hickelsberger; Gregor Bauer; Jürgen König
Journal:  PeerJ       Date:  2015-10-22       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.